[Non-cytostatic treatment of @entity5 . Anti- @entity2225 monoclonal antibody (Rituximab, Mabthera) in the treatment of XXXX ].

@entity1 @entity706 @entity5 @entity2225 @entity1072 @entity1893
Some types of @entity1893 cannot be treated by contemporary preparations. After repeated relapses and chemotherapy moreover damage of bone marrow occurs and further intense cytostatic treatment is not possible. Monoclonal antibodies against structures on @entity5 cells are an interesting alternative of cytostatic treatment. In 2000 the authors administered anti @entity2225 monoclonal antibody (rituximab, Mabthera Roche), 375 mg/m2, on the 1st, 8th, 15th and 22nd day i.v. to a total of 24 @entity1 with relapsing @entity1893 . In five @entity1 the relapse developed after high dosage chemotherapy and autologous transplantation of peripheral stem cells. Treatment was well tolerated with minimal side-effects. Favourable therapeutic results were recorded in @entity1 with @entity706 (70% of the therapeutic responses), small @entity1072 (64% of therapeutic responses) and in @entity1 with a relapse after autologous transplantations (80% of therapeutic responses). Anti @entity2225 monoclonal antibody is a new effective alternative of cytostatic treatment. Its position in the therapeutic strategy in @entity1 with @entity1893 awaits elaboration.
